Humacyte, Inc

May 13, 2016

Humacyte launches pivotal trial for lab-grown blood vessel

MARK HOLLMER for MASSDEVICE – Humacyte is launching a Phase III study of its lab-grown blood vessel Humacyl in 350 patients with end-stage renal disease who are on hemodialysis and don’t qualify for a standard surgical treatment, and Boston’s Brigham & Women’s Hospital plans…

Read More »
May 13, 2016

Humacyte Commences Phase III Clinical Trial of Human Acellular Vessel

International Study of Humacyte’s Investigational Tissue-Engineered Vascular Conduit for Hemodialysis (HUMANITY®) will be the Largest of its Kind to Date RESEARCH TRIANGLE PARK, N.C. – May 13, 2016 – Humacyte, an innovator in biotechnology and regenerative medicine, announced today the commencement of a Phase…

Read More »